Expand Document | Expand Chapter | Full TOC | Printable HTML version
Safety of Medicines - A Guide to Detecting and Reporting Adverse Drug Reactions - Why Health Professionals Need to Take Action
(2002; 16 pages)
Table of Contents
View the documentIntroduction
View the documentGlossary
View the documentThe magnitude of the problem
View the documentWhy postmarketing surveillance and reporting ADR is needed
View the documentWhy pharmacovigilance is needed in every country
View the documentHow voluntary reporting on ADRs can prevent new medicine tragedies from developing
View the documentHow voluntary reporting on ADRs can influence labelling
View the documentWhy health professionals are in the best position to detect and report on ADRs
View the documentHow to recognize ADRs
View the documentWhat should be reported?
View the documentHow to report ADRs?
View the documentReferences
View the documentAcknowledgements
 

How voluntary reporting on ADRs can prevent new medicine tragedies from developing

It took many decades before the deleterious effects of aspirin on the gastro-intestinal tract became apparent and almost as long before it was recognised that the protracted abuse of phenacetin could produce renal papillary necrosis; 35 years elapsed before it became clear that amydopyrine could cause agranulocytosis; and several years before the association of phocomelia with thalidomide became obvious8.

Withdrawals from the market as a result of spontaneous reporting

INN (brand name)

Reason for withdrawal

Year of marketing

Year of withdrawal

bromfenac (Duract®)

serious hepatotoxic effect

1997

1998

encainide (Enkaid®)

excessive mortality

1987

1991

flosequinan (Manoplax®)

excessive mortality

1992

1993

temafloxacin (Omniflox®)

haemolytic anemia

1992

1992

benoxaprofen (Oraflex®)

liver necrosis

1982

1982

mibefradil (Posicor®)

multiple drug interaction

1997

1998

terfenadine (Seldane®)

fatal cardiac arrythmias

1985

1998

After the “thalidomide tragedy” many countries have established drug monitoring systems for early detection and prevention of possible drug-related morbidity and mortality. Their success depends on the cooperation of the medical profession in reporting suspected ADRs, especially to new drugs.

Some examples demonstrate how very astute, alert and observant medical doctors have been helped to prevent the development of drug morbidity and drug mortality by reporting on suspected ADRs which resulted in the withdrawal of dangerous drugs from the market or in restriction of their use.

to previous section to next section
 

Last updated: May 3, 2013